Last edition
News about "Kinvard Bio "
Kinvard Bio has secured USD 2.7 million in follow-on non-dilutive funding from CARB-X to advance its novel ribosome-targeting antibiotics toward preclinical development, tackling drug-resistant infections like MRSA and cUTI.
Kinvard Bio | 29/07/2025 | By Mrinmoy Dey | 178
Kineticos Launches Kinvard Bio to Power Next-Gen Antibiotics
KAMRA I is dedicated to combating antimicrobial resistance (AMR) by investing in, creating, and supporting companies that are developing disruptive solutions to address this critical public health issue.
Kinvard Bio | 25/02/2025 | By Aishwarya | 219
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy